Countries covered: Global
This report analyzes the worldwide markets for Cardiac Biomarkers in US$ Million. The market is analyzed by Location-wise (Clinical Laboratory Testing, and Point-of-Care Testing) and by Assay types (Acute Myocardial Infarction (AMI) Tests (Creatine Kinase-MB (CK-MB), Cardiac Troponin, & Myoglobin), and Congestive Heart Failure (CHF) Tests (BNP &NT-proBNP)). The report provides separate omprehensive analytics for the US, Europe, and Rest of the World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 58 companies including many key and niche players such as Abbott Diagnostics, Alere, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., BG Medicine, biomérieux, LifeSign LLC, Nanogen Inc., Ortho-Clinical Diagnostics, Inc., Prognostix, Inc., Response Biomedical Corp., Roche Diagnostics Corp., and Siemens Healthcare Diagnostics, Inc..Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
|
- 1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- 2. INDUSTRY OVERVIEW
- Cardiovascular Diseases: Leading cause of Mortality Worldwide
- Table 1: A Review of Region-Wise Incidence andPrevalence of Cardiovascular Diseases:
- Basic Topologies of Cardiovascular Diseases
- Table 2: Leading Causes of Death in Low Income Nations (includes corresponding Graph/Chart)
- Table 3: Leading Causes of Death in Middle Income Nations (includes corresponding Graph/Chart)
- Table 4: Leading Causes of Death in High Income Nations (includes corresponding Graph/Chart)
- Cardiac Biomarkers: A Snapshot
- Fast and Accurate Diagnosis - Reduce Unnecessary Healthcare Costs
- Cardiac Biomarkers - Making Diagnosis Easier and Quicker
- What is a Cardiac BioMarker
- Necessity of a Cardiac Marker Assay Test
- How it works?
- Major Cardiac Markers and their Properties
- Market Analysis
- Market Trends
- Strong Demand for Risk Assessment Markers
- Intense Competition among Players in the Cardiac Diagnostics Market
- Siemens Healthcare: World’s Largest Fully Integrated Diagnostics Company
- Product Portfolio of Bayer and Dade Behring
- The Future of Cardiac Marker POCT Segment
- Need for Early Detection Markers
- Rapid Turnaround time: A Crucial Parameter for POC Testing Kits
- Stroke Biomarkers: A Review
- Player Initiatives in the Recent Years
- 3. TRENDS IN RESEARCH AND DEVELOPMENT
- Increasing Health Burden Drives Research Efforts
- High-Performance Techniques Drive Biomarker Discovery in Cardiology
- Effective Phenotyping Takes Precedence for Successful Genotyping Studies
- Biomarkers of ACS: A Leading Segment
- Biomarkers - A Promising Diagnostic Tool for ACS
- New Diagnostic Biomarkers for ACS on the Anvil
- Biomarker Discovery in Cardiovascular Diseases to Undergo Significant Changes
- Genomic Biomarkers for Detecting Cardiovascular Diseases
- Growing Demand for Stroke Biomarkers
- Rising Incidence of the Disease - A Major Driver for Stroke Biomarkers
- 4. CARDIAC MARKERS AND MYOCARDIAL INFARCTION
- Chain Reaction after an Event of MI
- Action Plan after an Event of MI
- Protocol for Conducting AMI Markers Tests
- Myocardial Infarction Cardiac Biomarkers - Benefits and Limitations
- Creatine Kinase - The Traditional Gold Standard, Loosing Sheen
- Market and Forecasts:
- Isomers
- Kinetics
- Purpose of Test and When to Order
- Evaluation
- Points to remember
- Cardiac Troponin - Taking Over from CK-MB
- Market and Forecast
- Overview
- Troponin Tissue-Specific Subtypes
- Other Diseases
- Uses of Troponin Tests
- New Advanced High-sensitivity (Hs) Cardiac Troponin Tests
- Myoglobin
- Purpose of Test and When to Order
- Testing and Evaluation
- Points to Remember
- Market and Forecast
- 5. CARDIAC MARKERS AND CONGESTIVE HEART FAILURE (CHF)
- Key Facts
- BNP (B-type Natriuretic Peptide)
- NT-proBNP (N-terminal proBNP)
- Purpose of Tests and When to Order
- Testing and Evaluation
- Points to Remember
- Market and Forecast
- Introduction of BNP Test and the Changing Market Scenario in the Segment: A Review
- Player Strategies in the BNP and NT-proBNP Testing Market: A Review
- Choosing the Right BNP and NT proBNP Assay Kit in the Market
- Evolution of BNP and NT proBNP Market
- NT-proBNP is superior to BNP in Predicting Mortality in Heart Failure Patients, with Reduced Kidney Function
- 6. OTHER IMPORTANT CARDIAC BIOMARKERS
- Homocysteine
- C-Reactive Protein
- Plasminogen Activator Inhibitor-
- D-Dimer
- Thrombus Precursor Protein
- Galectin-3 Biomarker
- Galectin-3: An Overview of Clinical Studies
- Galectin-3: Overview of Clinical Studies in Cardiovascular Disease Diagnosis
- Potential Future Cardiac Biomarkers
- 7. CARDIAC BIOMARKER TESTING IN CLINICAL LABORATORIES
- Market and Forecast
- 8. CARDIAC BIOMARKERS AT POINT-OF- CARE TESTING
- Market and Forecast
- Major Players Operating in the Cardiac Markers POCT Segment
- Cardiac Markers Point-of-Care testing (POCT) Segment: Major Players & Their Operating Brands.
- 9. STRATEGIC CORPORATE DEVELOPMENTS
- BG Medicine and Boston Scientific Partner for Collaborative Research
- HDL and Gamma Therapeutics to Offer Biomarker Assay Tests for Risk Assessment of Stroke and Heart attack
- Pacific Biomarkers Enters into Research Deals with Two Multinational Firms
- Roche Enters into Cross-Licensing Agreement with Alere
- ACC and Roche Diagnostics Initiate Collaboration
- Aushon BioSystems Enters into Partnership with LightArray Biotech
- Inverness Medical Innovations Changes Name to Alere
- BG Medicine Inks Agreement with LabCorp
- Siemens and Eko Diagnostics to Establish a PET Biomarkers Manufacturing
- Caprion Takes over PPD’s Biomarker Business
- Corgenix Medical Inks Supply Agreement with BG Medicine
- ELITech Buys Out Nanogen Assets
- Cordex and BG Medicine to join Forces for Clinical Investigation of Biomarkers for Cardiac Failure
- Asbach and Oxford Biosystems Ink Distribution Agreements with Athera
- GCIC Grants Funds to Prognostix to Further Product Development
- Thermo Fisher Scientific Takes over B.R.A.H.M.S
- Response Biomedical Signs Partnership Agreement with Roche
- Compugen Announces Discovery of Troponin I Biomarker Variant, Inks Agreement with Biosite
- Inverness Acquires Biosite
- Siemens Acquires Diagnostic Division of Bayer Healthcare
- Siemens Announces Acquisition of Dade Behring
- Beckman Collaborates in CVD Related Research Projects
- Dade Behring Receives Sublicense to New Cardiac Marker
- Inverness Acquires Cholestech
- Response Biomedical Secures Clearance to Market RAMP® NT-proBNP Test
- Acrongenomics Collaborates with Molecular Vision and Pearson Matthews
- BG Medicine Obtains Rights to Develop Tests for Congestive Heart Failure
- Nanogen Gains US Reissue Patent for Combined Use of Biomarkers for CHF Diagnosis
- Nanogen Secures FDA Approval for CHF NT-proBNP EDTA Plasma Test
- Roche Diagnostics Secures FDA Approval for Roche Elecsys® proBNP Test
- Nanogen Acquires Rapid Cardiac Immunoassay Test Businesses of SDI
- Response Biomedical Starts Clinical Trials of the RAMP NT- proBNP Test
- Procter and Gamble, Inverness to Form JV for Consumer Diagnostics
- Roche Diagnostics Grants Rights for NT- proBNP to Mitsubishi Kagaku Latron
- Bayer Healthcare Receives FDA Approval for Troponin-I-Test Tnl-Ultra
- MKI Obtains EU Approval and CE Mark for Four Cardiac Markers
- Dade Behring Grants PIGF Rights to Abbott
- Siemens and PETNET Pharmaceuticals Acquire PETNET’s New England Operations
- OXIS International Acquires Biocheck
- Wampole, Roche collaborate on Ischemia Modified Albumin Test
- Nanogen Extends Point-of-Care Diagnostic Tests Distribution in Europe
- Abbott, Cleveland Clinic Agrees to Develop MPO Cardiac Test
- Roche Diagnostics Grants Rights to Response Biomedical for Troponin T and NT- proBNP
- Inverness Acquires Ischemia Technologies
- Roche Diagnostics Grants Rights for NT- proBNP to bioMerieux
- Roche Confers Rights of NT-proBNP to Ortho-Clinical Diagnostics
- Dade Behring Grants CRP Sublicense to Roche Diagnostics
- Roche Awards Non Exclusive Rights of NT-proBNP marker to DPC
- Abbott Gains Approval for CK-MB Test in the US
- i-STAT Gains Approval for Troponin I Test from US FDA
- 10. PRODUCT LAUNCHES/DEVELOPMENTS/ APPROVALS
- Eisai and Sanko to Unveil Cobas h 232 Series
- bioMerieux and Philips Co-Develop an Advanced Rapid POCT Solution for Emergency Testing
- Singulex Secures US patent for use of Erenna Technology in Diagnosing Low Troponin-I Levels
- BG Medicine Receives FDA Clearance for Galactin-3 Assay
- Roche Launches STAT Immunoassays Module
- Alere International Launches New Triage® NT-proBNP Test
- Abbott Laboratories and BG Medicine Ink Agreement
- PGxHealth Unveils Familion DCM Genetic Test
- Roche Diagnostics Launches Cardiac
- Thermo Fisher Scientific Introduces Biomarker based Diagnostics for Heart Attack in Europe
- Alere Introduces Triage® NT-proBNP Test
- Celera Inks Non-Exclusive License Agreement with Perlegen Sciences
- Maine Standards Launches VALIDATE CM2 Test Set
- Response Bags FDA Clearance for RAMP® NT-proBNP Test
- bioMérieux Rolls out VIDAS® NT-proBNP
- Roche Diagnostics Introduces Cobas-H-232 Handheld Cardiac Marker System
- OXIS Discovers a Unique Diagnostic Biomarker for Cardiovascular Disease
- Ortho-Clinical Presents Sensitivity Troponin I Test, VITROS Troponin I ES
- bioMerieux Unveils ‘VIDAS® Troponin I Ultra’
- Roche Elecsys proBNP Assay Secures FDA Clearance
- Bayer Launches New Tnl-Ultra™ Troponin Assay on ADVIA Centaur® CP Immunoassay system
- Ortho-Clinical Diagnostics Receives FDA Clearance for VITROS NT-proBNP Assay
- Dade Behring Launches CardioPhase® hsCRP Test
- Diagnostic Products Corporation to Market NT-proBNP Outside US
- Dade Behring Introduces Homocysteine Assay for BN™ System
- Biosite Develops Triage® Cardio ProfilER™ Panel
- A Breakthrough Biochip Array System for MI
- FDA Approves Emergency Department Diagnostic Test from Biosite
- Response Biomedical Obtains Regulatory Clearance for RAMP®
- Response Biomedical Gains US FDA Approval for 3rd RAMP® Test
- CLINIQA Rolls Out Liquid Stable Cardiac Marker Controls
- Abbott Releases AxSYM® Troponin-I ADV Assay in World Markets
- 11. FOCUS ON SELECT GLOBAL PLAYERS
- Abbott Diagnostics (USA)
- Alere, Inc. (USA)
- Ani Biotech Oy (Finland)
- Axis-Shield PoC (UK)
- Beckman Coulter, Inc. (USA)
- BG Medicine (USA)
- biomérieux (France)
- LifeSign LLC (USA)
- Ortho-Clinical Diagnostics, Inc. (USA)
- Prognostix, Inc. (USA)
- Response Biomedical Corp. (Canada)
- Roche Diagnostics Corp. (USA)
- 12. GLOBAL MARKET PERSPECTIVE
- Table 5: World Recent Past, Current and Future Analysisfor Cardiac Biomarkers by Geographic Region -US, Europe, and Rest of the World MarketsIndependently Analyzed with Annual Sales Figuresin US$ million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 6: World Historic Review Analysis for CardiacBiomarkers by Geographic Region - US, Europe, andRest of the World Markets Independently Analyzed withAnnual Sales Figures in US$ million for Years 2003through 2008 (includes corresponding Graph/Chart)
- Table 7: World 15-Year Perspective for CardiacBiomarkers by Geographic Region - US, Europe,and Rest of the World Markets Independently Analyzedwith Annual Sales Figures in US$ million for Years 2003,2010, and 2017 (includes corresponding Graph/Chart)
- Table 8: World Recent Past, Current and FutureAnalysis for Cardiac Biomarkers in LaboratoryTesting Sector by Geographic Region - US, Europe,and Rest of the World Markets Independently Analyzedwith Annual Sales Figures in US$ million for Years 2009through 2017 (includes corresponding Graph/Chart)
- Table 9: World Historic Review Analysis for CardiacBiomarkers in Laboratory Testing Sector by GeographicRegion - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figuresin US$ million for Years 2003 through 2008(includes corresponding Graph/Chart)
- Table 10: World 15-Year Perspective for CardiacBiomarkers in Laboratory Testing Sector by GeographicRegion - US, Europe, and Rest of the World MarketsIndependently Analyzed with Annual Sales Figuresin US$ million for Years 2003, 2010, and 2017(includes corresponding Graph/Chart)
- Table 11: World Recent Past, Current and FutureAnalysis for Cardiac Biomarkers in Point-of-Care TestingSector by Geographic Region - US, Europe, andRest of the World Markets Independently Analyzedwith Annual Sales Figures in US$ million for Years 2009through 2017 (includes corresponding Graph/Chart)
- Table 12: World Historic Review Analysis for Cardiac Biomarkers in Point-of-Care Testing Sector by Geographic Region - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figuresin US$ million for Years 2003 through 2008(includes corresponding Graph/Chart)
- Table 13: World 15-Year Perspective for CardiacBiomarkers in Point-of-Care Testing Sector by Geographic Region - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figuresin US$ million for Years 2003, 2010, and 2017(includes corresponding Graph/Chart)
- Table 14: World Recent Past, Current & Future Analysisfor CK-MB Assay Test by Geographic Region - US,Europe and Rest of the World Markets. IndependentlyAnalyzed with Annual Sales Figures in US$ millionfor Years 2006 through 2017 (includescorresponding Graph/Chart)
- Table 15: World Historic Review Analysis for CK-MBAssay Test by Geographic Region - US, Europe andRest of the World Markets. Independently Analyzedwith Annual Sales Figures in US$ million for Years 2003through 2008 (includes corresponding Graph/Chart)
- Table 16: World 15-Year Perspective for CK-MBAssay Test by Geographic Region - US, Europe andRest of the World Markets. Independently Analyzedwith Annual Sales Figures in US$ millionfor Years 2003, 2010, and 2017 (includescorresponding Graph/Chart)
- Table 17: World Recent Past, Current & Future Analysisfor Cardiac Troponin Assay Test by Geographic Region -US, Europe and Rest of the World Markets. IndependentlyAnalyzed with Annual Sales Figures in US$ millionfor Years 2009 through 2017 (includescorresponding Graph/Chart)
- Table 18: World Historic Review Analysis for CardiacTroponin Assay Test by Geographic Region - US, Europeand Rest of the World Markets. Independently Analyzedwith Annual Sales Figures in US$ million for Years 2001through 2005 (includes corresponding Graph/Chart)
- Table 19: World 15-Year Perspective for Cardiac TroponinAssay Test by Geographic Region - USA, Europe andRest of the World Markets. Independently Analyzed withAnnual Sales Figures in US$ million for Years 2006,2009, and 2017 (includes corresponding Graph/Chart)
- Table 20: World Recent Past, Current & Future Analysisfor Myoglobin Assay Test by Geographic Region - US,Europe and Rest of the World Markets. IndependentlyAnalyzed with Annual Sales Figures in US$ millionfor Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 21: World Historic Review Analysis for MyoglobinAssay Test by Geographic Region - US, Europe andRest of the World Markets. Independently Analyzedwith Annual Sales Figures in US$ million forYears 2003 through 2008 (includes correspondingGraph/Chart)
- Table 22: World 15-Year Perspective for MyoglobinAssay Test by Geographic Region - US, Europe andRest of the World Markets. Independently Analyzedwith Annual Sales Figures in US$ million for Years 2003,2010, and 2017 (includes corresponding Graph/Chart)
- Table 23: World Recent Past, Current & Future Analysisfor BNP & NT-proBNP Assay Test by Geographic Region -US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ millionfor Years 2009 through 2017 (includescorresponding Graph/Chart)
- Table 24: World Historic Review Analysis for BNP &NT-proBNP Assay Test by Geographic Region - US,Europe and Rest of the World Markets. IndependentlyAnalyzed with Annual Sales Figures in US$ millionfor Years 2003 through 2008 (includescorresponding Graph/Chart)
- Table 25: World 15-Year Perspective for BNP & NT-proBNP Assay Test by Geographic Region - US, Europeand Rest of the World Markets. Independently Analyzedwith Annual Sales Figures in US$ millionfor Years 2003, 2010, and 2017 (includescorresponding Graph/Chart)
- 13. THE UNITED STATES
- A. Market Analysis
- Cardiovascular Diseases in the US: A Review
- Heart Facts
- Table 26: The US Disease Statistics for CoronaryHeart Disease (CHD) & MyocardialInfarction (MI)
- Table 27: Prevalence of Cardiovascular Diseasesin the US by Type (2007-2009) (includescorresponding Graph/Chart)
- Table 28: The US Prevalence of Coronary HeartDisease (CHD) as a Percentage of Total Populationby Age-group & Sex, in 2005 - 06. (includescorresponding Graph/Chart)
- Table 29: The US Annual Number of New &Recurrent Adults diagnosed with Heart Attackby Age & Sex in the Recent Past (includescorresponding Graph/Chart)
- Table 30: The US Disease Statistics forHeart Failure
- Table 31: The Annual Number of AmericansDiagnosed with Heart Failure as 'per 1000 persons'by Age & Sex, in the Recent Past (includescorresponding Graph/Chart)
- Number of Deaths due to Heart Diseases & Strokes: A Historic Review
- Senior Citizens at High Risk for Heart Failure
- CHF Biomarkers to Spearhead the US market
- US Cardiac Markers POCT Segment
- Table 32: US AMI (Acute Myocardial Infarction) Diagnostics Market: Market Share by Revenue heldby Major Players (Siemens, Beckman Coulter,and Others) in 2010(E) (includescorresponding Graph/Chart)
- Table 33: US CHF (Congestive Heart Failure)Diagnostics Market: Market Share by Revenueheld by Major Players (Siemens, Alere,Beckman Coulter, and Others) in 2010(E)(includes corresponding Graph/Chart)
- Product Launches/Approvals/Developments
- Strategic Corporate Developments
- Focus on Select Key Players
- Abbott Diagnostics
- Beckman Coulter, Inc.
- BG Medicine (USA)
- diaDexus, Inc.
- Inverness Medical Innovations, Inc.
- LifeSign LLC
- Ortho-Clinical Diagnostics, Inc.
- Prognostix, Inc.
- Roche Diagnostics Corp.
- Siemens Healthcare Diagnostics, Inc.
- B. Market Analytics
- Table 34: The US Recent Past, Current and Future Analysisfor Cardiac Markers by Segment - Clinical Laboratorytesting and Point-of-Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 35: The US Historic Review Analysis for CardiacMarkers by Segment - Clinical Laboratory testingand Point-of-Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for Years 2003 through 2008(includes corresponding Graph/Chart)
- Table 36: The US 15-Year Perspective for CardiacMarkers by Segment - Clinical Laboratory testingand Point-of- Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for 2003, 2010 and 2017(includes corresponding Graph/Chart)
- Table 37: The US Recent Past, Current and FutureAnalysis for Cardiac Markers by Test Type -AMI (CK-MB, Cardiac Troponin and Myoglobin),and CHF (BNP and NT proBNP) Markets:Independently Analyzed with Annual Salesin US$ million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 38: The US Historic Review Analysis for CardiacMarkers by Test Type - AMI (CK-MB, CardiacTroponin and Myoglobin), and CHF (BNP andNT proBNP) Markets: Independently Analyzedwith Annual Sales in US$ million for Years2003 through 2008 (includes correspondingGraph/Chart)
- Table 39: The US 15-Year Perspective for CardiacMarkers by Test Type - AMI (CK-MB, CardiacTroponin and Myoglobin), and CHF (BNP andNT proBNP) Markets: Independently Analyzedwith Annual Sales in US$ million for 2003,2010 and 2017 (includes correspondingGraph/Chart)
- 14. EUROPE
- A. Market Analysis
- European Cardiovascular Diseases Fact Sheet
- Evolution of the European Cardiac Risk Markers Market
- Cardiac Markers in Primary Care Sector
- Product Launches/Approvals/Developments
- Strategic Corporate Developments
- B. Market Analytics
- Table 40: European Recent Past, Current and Future Analysis for Cardiac Markers by Region - France,Germany, Italy, UK, and ‘Rest of Europe’ Markets: Independently Analyzed with Annual Salesin US$ million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 41: European Historic Review Analysis forCardiac Markers by Region - France, Germany,Italy, UK, and ‘Rest of Europe’ Markets: Independently Analyzed with Annual Sales in US$ million forYears 2003 through 2008 (includescorresponding Graph/Chart)
- Table 42: European 15-Year Perspective for Cardiac Markers by Region - France, Germany, Italy, UK,and ‘Rest of Europe’ Markets: IndependentlyAnalyzed with Annual Sales in US$ millionfor 2003, 2010 and 2017 (includescorresponding Graph/Chart)
- Table 43: European Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Salesin US$ million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 44: European Historic Review Analysis forCardiac Markers by Segment - Clinical Laboratorytesting and Point-of-Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for Years 2003 through 2008(includes corresponding Graph/Chart)
- Table 45: European 15-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testingand Point-of-Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for 2003, 2010 and
- Table 46: European Recent Past, Current and Future Analysis for Cardiac Markers by Assay Test Type -AMI (CK-MB, Cardiac Troponin and Myoglobin),and CHF (BNP and NT proBNP) Markets:Independently Analyzed with Annual Salesin US$ million for Years 2009 through2017 (includes corresponding Graph/Chart)
- Table 47: European Historic Review Analysis forCardiac Markers by Assay Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNPand NT proBNP) Markets: Independently Analyzedwith Annual Sales in US$ million forYears 2003 through 2008 (includescorresponding Graph/Chart)
- Table 48: European 15-Year Perspective for Cardiac Markers by Assay Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NTproBNP) Markets: Independently Analyzed withAnnual Sales in US$ million for 2003, 2010 and2017 (includes corresponding Graph/Chart)
- 14a. FRANCE
- A. Market Analysis
- Product Launches/Approvals/Developments
- Strategic Corporate Developments
- BioMérieux - A Key Player
- B. Market Analytics
- Table 49: French Recent Past, Current and FutureAnalysis for Cardiac Markers by Segment -Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: IndependentlyAnalyzed with Annual Sales in US$ millionfor Years 2009 through 2017 (includescorresponding Graph/Chart)
- Table 50: French Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testingand Point-of-Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for Years 2003 through 2008(includes corresponding Graph/Chart)
- Table 51: French 15-Year Perspective for CardiacMarkers by Segment - Clinical Laboratory testingand Point-of-Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for 2003, 2010 and 2017(includes corresponding Graph/Chart)
- 14b. GERMANY
- A. Market Analysis
- Rennesens GmbH
- Strategic Corporate development
- B. Market Analytics
- Table 52: German Recent Past, Current and FutureAnalysis for Cardiac Markers by Segment -Clinical Laboratory testing and Point-of-CareTesting (POCT) Markets: IndependentlyAnalyzed with Annual Sales in US$ millionfor Years 2009 through 2017 (includescorresponding Graph/Chart)
- Table 53: German Historic Review Analysis forCardiac Markers by Segment - Clinical Laboratorytesting and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Salesin US$ million for Years 2003 through 2008(includes corresponding Graph/Chart)
- Table 54: German 15-Year Perspective for CardiacMarkers by Segment - Clinical Laboratory testingand Point-of-Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for 2003, 2010 and 2017(includes corresponding Graph/Chart)
- 14c. ITALY
- Market Analysis
- Table 55: Italian Recent Past, Current and FutureAnalysis for Cardiac Markers by Segment -Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: IndependentlyAnalyzed with Annual Sales in US$ million forYears 2009 through 2017 (includescorresponding Graph/Chart)
- Table 56: Italian Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testingand Point-of-Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for Years 2003 through 2008(includes corresponding Graph/Chart)
- Table 57: Italian 15-Year Perspective for CardiacMarkers by Segment - Clinical Laboratory testingand Point-of- Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for 2003, 2010 and 2017(includes corresponding Graph/Chart)
- 14d. THE UNITED KINGDOM
- A. Market Analysis
- UK Cardiovascular Diseases Fact Sheet
- Table 58: The UK’s Healthcare Costs of CardioVascular Diseases (CVD), CoronaryHeart Diseases (CHD) & Strokesin 2006 (includes correspondingGraph/Chart)
- Strategic Corporate Development
- Product Launch
- Axis-Shield PoC: A Key Player
- B. Market Analytics
- Table 59: The UK Recent Past, Current and FutureAnalysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Salesin US$ million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 60: The UK Recent Past, Current and FutureAnalysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Salesin US$ million for Years 2003 through 2008(includes corresponding Graph/Chart)
- Table 61: The UK 15-Year Perspective for CardiacMarkers by Segment - Clinical Laboratory testingand Point-of- Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for 2003, 2010 and 2017(includes corresponding Graph/Chart)
- 14e. REST OF EUROPE
- A. Market Analysis
- Ani Biotech Oy: A Key Player
- B. Market Analytics
- Table 62: Rest of Europe Recent Past, Currentand Future Analysis for Cardiac Markers bySegment - Clinical Laboratory testing andPoint-of-Care Testing (POCT) Markets:Independently Analyzed with Annual Salesin US$ million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 63: Rest of Europe Recent Past, Current andFuture Analysis for Cardiac Markers by Segment -Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed withAnnual Sales in US$ million for Years 2001through 2005 (includes correspondingGraph/Chart)
- Table 64: Rest of Europe 15-Year Perspective forCardiac Markers by Segment - Clinical Laboratorytesting and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Salesin US$ million for 2003, 2010 and 2017(includes corresponding Graph/Chart)
- 15. REST OF WORLD
- A. Market Analysis
- Evolution of BNP Test market in Japan
- Canada: cardiovascular disease facts
- Table 65: Heart Disease in Canada by Province:an Overview (includes corresponding Graph/Chart)
- Heart Attacks
- Cardiac Arrest
- Heart Failure
- Stroke
- Congenital Heart Disease
- Product Launches/Approvals/Developments
- Strategic Corporate Developments
- Focus on Select Key Players
- Response Biomedical Corporation
- Sekisui Medical Co. Ltd.
- Shionogi and Co. Ltd.
- B. Market Analytics
- Table 66: Rest of the World Recent Past, Current andFuture Analysis for Cardiac Markers by Segment -Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed withAnnual Sales in US$ million for Years 2006through 2017 (includes corresponding Graph/Chart)
- Table 67: Rest of the World Historic ReviewAnalysis for Cardiac Markers by Segment -Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: IndependentlyAnalyzed with Annual Sales in US$ million forYears 2003 through 2008 (includescorresponding Graph/Chart)
- Table 68: Rest of the World 15-Year Perspectivefor Cardiac Markers by Segment - ClinicalLaboratory testing and Point-of-CareTesting (POCT) Markets: IndependentlyAnalyzed with Annual Sales in US$ millionfor 2003, 2010 and 2017 (includescorresponding Graph/Chart)
- Table 69: Rest of the World Recent Past, Currentand Future Analysis for Cardiac Markers byAssay Test Type - AMI (CK-MB, CardiacTroponin and Myoglobin), and CHF (BNP andNT proBNP) Markets: Independently Analyzedwith Annual Sales in US$ million for Years2009 through 2017 (includes correspondingGraph/Chart)
- Table 70: Rest of the World Historic ReviewAnalysis for Cardiac Markers by Assay Test Type -AMI (CK-MB, Cardiac Troponin andMyoglobin), and CHF (BNP andNT proBNP) Markets: IndependentlyAnalyzed with Annual Sales in US$ millionfor Years 2003 through 2008 (includescorresponding Graph/Chart)
- Table 71: Rest of the World 15-Year Perspective forCardiac Markers by Test Type - AMI (CK-MB,Cardiac Troponin and Myoglobin), and CHF(BNP and NT proBNP) Markets: IndependentlyAnalyzed with Annual Sales in US$ millionfor 2003, 2010 and 2017 (includescorresponding Graph/Chart)
- COMPETITIVE LANDSCAPE
- Total Companies Profiled: 58 (including Divisions/Subsidiaries - 75)Region/Country Players
- The United States
- Canada 4
- Japan 3
- Europe
- France
- Germany
- The United Kingdom
- Spain
- Rest of Europe 9
- Asia-Pacific (Excluding Japan) 13
- Latin America 1
- Middle-East 2
More Global Medical Devices Company Reports
Surgical Sutures - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018 by
GlobalData
Surgical Sutures - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018 Summary GlobalData’s new report, “Surgical Sutures - Global Opportunity Assessment, Competitive Landscape and Market ...
Siemens in the World Healthcare Sector by
Venture Planning Group
A strategic assessment of Siemens, one of the world's leading healthcare companies, provides significant competitor information, analysis and insight critical to the development and implementation ...
The Guide to Distributors of Medical Equipment & Supplies Worldwide 2012 Volume IV:Asia/Pacific by
Espicom Healthcare Intelligence
426 specialist medical sales companies in 22 countries from Australia and Bangladesh to Thailand and Vietnam
These days we must all work harder to ...
The Guide to Distributors of Medical Equipment & Supplies Worldwide 2012 Volume III: Americas by
Espicom Healthcare Intelligence
386 specialist medical sales companies in 28 countries from Argentina and Bahamas to the USA and Venezuela
These days we must all work harder ...
The Guide to Distributors of Medical Equipment & Supplies Worldwide 2012 Volume II:Middle East/Africa by
Espicom Healthcare Intelligence
372 specialist medical sales companies in 38 countries from Algeria and Bahrain to Yemen and Zimbabwe
These days we must all work harder to ...
See all reports like this >>
Share this report
Other tasks Related Markets Medical Devices Company Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
